OPKO Health, Inc. Ratifies the Appointment of Ernst & Young LLP as the Independent Registered Public Accounting Firm for the Fiscal Year Ending December 31, 2021 At the AGM Held on June 24, 2021
June 25, 2021 at 04:26 pm EDT
Share
OPKO Health, Inc. ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2021 at the AGM held on June 24, 2021.
OPKO Health, Inc. is a multinational biopharmaceutical and diagnostics company. The Company's diagnostics segment consists of the clinical laboratory operations of BioReference Health, LLC (BioReference), its point-of-care operations. Its pharmaceutical segment consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. Through BioReference, it operates specialized laboratory divisions, such as GenPath (Urology), GenPath (Oncology), and GenPath (Women's Health). It has two commercial stage pharmaceutical products and several pharmaceutical compounds and technologies in various stages of research and development for a range of indications and conditions, including Rayaldee, Rayaldee, Oxyntomodulin, Biologics, NGENLA Somatrogon, and Factor VIIa-CTP. It develops and manufactures specialty active pharmaceutical ingredients (APIs) through FineTech Pharmaceutical, Ltd.
OPKO Health, Inc. Ratifies the Appointment of Ernst & Young LLP as the Independent Registered Public Accounting Firm for the Fiscal Year Ending December 31, 2021 At the AGM Held on June 24, 2021
OPKO HEALTH, INC. 
